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OBJECTIVE—Twist1 is a transcription factor that is highly
expressed in murine brown and white adipose tissue (WAT) and
negatively regulates fatty acid oxidation in mice. The role of
twist1 in WAT is not known and was therefore examined.
RESEARCH DESIGN AND METHODS—The expression of
twist1 was determined by quantitative real-time PCR in different
tissues and in different cell types within adipose tissue. The effect
of twist1 small interfering RNA on fatty acid oxidation, lipolysis,
adipokine secretion, and mRNA expression was determined in
human adipocytes. The interaction between twist1 and speciﬁc
promoters in human adipocytes was investigated by chromatin
immunoprecipitation (ChIP) and reporter assays.
RESULTS—Twist1 was highly expressed in human WAT com-
pared with a set of other tissues and found predominantly in
adipocytes. Twist1 levels increased during in vitro differentiation
of human preadipocytes. Gene silencing of twist1 in human white
adipocytes had no effect on lipolysis or glucose transport.
Unexpectedly, and in contrast with results in mice, twist1 RNA
interference reduced fatty acid oxidation. Furthermore, the
expression and secretion of the inﬂammatory factors tumor
necrosis factor-, interleukin-6, and monocyte chemoattractant
protein-1 were downregulated by twist1 silencing. ChIP and
reporter assays conﬁrmed twist1 interaction with the promoters
of these genes.
CONCLUSIONS—Twist1 may play a role in inﬂammation of
human WAT because it can regulate the expression and secretion
of inﬂammatory adipokines via direct transcriptional effects in
white adipocytes. Furthermore, twist1 may, in contrast to ﬁnd-
ings in mice, be a positive regulator of fatty acid oxidation in
human white adipocytes. Diabetes 59:564–571, 2010
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wist1 and twist2 are well-conserved basic helix-
loop-helix transcription factors (1,2). They dimer-
ize with other basic helix-loop-helix proteins and
bind to E-boxes in the promoter regions of their
target genes (3). The human twist proteins are highly homol-
ogous, although twist2 (previously Dermo1) is shorter than
twist1 due to an NH2-terminal truncation. Twist1 and
twist2 have partly overlapping functions but twist1 has
been more extensively studied. Twist1-null mice die dur-
ing embryogenesis due to failed neural tube fusion,
whereas Twist2
/ mice, although growth retarded, sur-
vive, implying that the two twist isoforms also have unique
effects (4). Twist2
/ animals display alterations in the
morphology and function of several tissues, including
adipose tissue, indicating an important role in organ
development (5). Moreover, twist1 and twist2 inhibit os-
teogenesis and myogenesis by blocking the activity of the
transcription factors Runx-2 and MyoD, respectively,
which are essential for differentiation (6–9). Increased
expression of twist1 is associated with tumor progression
and metastasis (10).
Local low-grade inﬂammation is an important factor
linking white adipose tissue (WAT) to insulin resistance and
ultimately type 2 diabetes (11). Twist2
/ and Twist1
//
Twist2
/ mice have increased circulating levels of the
inﬂammatory cytokines tumor necrosis factor- (TNF-),
interleukin (IL)-1, and IL-6, implying a role in inﬂamma-
tion (5). Twist1 expression in T helper 1 lymphocytes and
bone marrow–derived macrophages attenuates the ex-
pression of interferon-, IL-2, and TNF- (12,13), further
implicating twist1 in the regulation of cytokine expression.
Moreover, twist1 inhibits the activity of cytokine promot-
ers in COS cells, partly through an interaction with nuclear
factor-B (5).
Twist1 was recently shown to be highly, selectively, and
similarly expressed in murine brown adipose tissue (BAT)
and WAT (14). Furthermore, twist1 was found to inhibit
the transcriptional activity of peroxisome proliferator–
activated receptor- coactivator-1 (PGC-1), which has a
central role in brown adipocytes. Knockdown of twist1 in
murine brown adipocytes induced the expression of genes
involved in oxidative metabolism and fatty acid (FA)
oxidation, for example, uncoupling protein 1 (UCP-1) and
carnitine palmitoyl transferase 1 (CPT-1), whereas twist1
overexpression in C2C12 myotubes resulted in a reduction
in PGC-1–stimulated FA oxidation (14). This identiﬁes a
novel role for twist1 in energy homeostasis by regulating
PGC-1–induced energy expenditure in BAT.
Taken together, in vitro as well as animal studies
suggest that twist1 regulates pathways involved in inﬂam-
mation and energy homeostasis, processes that are closely
involved in the development of obesity and its associated
disorders, for example, insulin resistance and type 2
diabetes (11). However, the function of twist1 in WAT is
not known. Because of the selective expression of twist1
in murine WAT and BAT and its role in energy regulation
in murine BAT, we hypothesized that twist1 might also be
important for adipocyte function in human WAT. We
therefore measured the expression of twist1 in human
white adipocytes and WAT. We performed in vitro studies
where twist1 was downregulated by RNA interference
(RNAi) in primary cultures of human adipocytes and
assessed the effects on gene expression and different
From the
1Karolinska Institutet, Department of Medicine, Huddinge, Lipid
Laboratory, NVS, Stockholm, Sweden; the
2Division of Surgery, Department
of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockhom,
Sweden; and
3INSERM, U858, Toulouse, France.
Corresponding author: Amanda T. Pettersson, amanda.pettersson@ki.se.
Received 8 July 2009 and accepted 29 November 2009. Published ahead of
print at http://diabetes.diabetesjournals.org on 10 December 2009. DOI:
10.2337/db09-0997.
© 2010 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
ORIGINAL ARTICLE
564 DIABETES, VOL. 59, MARCH 2010 diabetes.diabetesjournals.orgaspects of fat cell function, including FA oxidation, basal
lipolysis, and adipokine secretion. Finally, the interaction
between twist1 and promoters was investigated by chro-
matin immunoprecipitation (ChIP) and reporter assays.
RESEARCH DESIGN AND METHODS
Patient samples. This study was conducted in accordance with the guide-
lines in the Declaration of Helsinki and approved by the ethics committee at
Karolinska University Hospital and at the Institutional Review Board of
INSERM and Toulouse University Hospital. The study was explained in detail
to each subject, and written informed consent was obtained.
In cohort 1, WAT, pancreas, liver, and skeletal muscle samples were
obtained from nonmalignant tissues of subjects undergoing elective surgery.
Cohort 2, described in detail elsewhere (15), comprised 14 healthy subjects (3
men and 11 women) (age 37.5  10 years; BMI 29.2  7 kg/m
2) from whom
mRNA of both intact subcutaneous WAT pieces and isolated adipocytes were
available. Biopsies of the subcutaneous abdominal WAT (0.5–2 g) were
obtained in the morning after an overnight fast by needle aspiration under
local anesthesia. In cohort 3, subcutaneous WAT was obtained from healthy
women undergoing elective surgical procedures of fat removal for esthetic
purposes (age 42.3  8.8 years; BMI 27.9  5.1 kg/m
2) (16). The cells from the
stroma-vascular fraction (SVF) and mature adipocytes from human WAT in
cohort 3 were obtained after collagenase digestion as previously described
(16). The different cell populations obtained from the SVF were capillary
endothelial cells, deﬁned as CD34
/CD31
; resident macrophages, deﬁned as
CD34
/CD14
; and cells negative for CD34, CD31, and CD14. Subjects in
cohorts 1 and 3 were not selected for age, sex, or BMI.
Cell culture. Cell culture experiments were performed on in vitro–differen-
tiated human adipocytes derived from preadipocytes isolated from WAT.
Isolation, culture, and differentiation of preadipocytes were performed as
previously described (17). For quantiﬁcation of twist1 mRNA during adipocyte
differentiation, preadipocytes were lysed at days 4, 8, and 12 of differentiation.
Small interfering RNA (siRNA) and ChIP experiments were performed at
differentiation days 10–12. For reporter assays, 3T3-L1 cells were grown
according to standard protocols from ATCC (Manassas, VA).
RNAi by siRNA. Human in vitro–differentiated adipocytes were treated with
50 nmol/l ON-TARGETplus SMARTpool TWIST1 (l-006434-00) siRNA (Thermo
Fisher Scientiﬁc, Lafayette, CO) and 9 l HiPerFect Transfection Reagent
(QIAGEN, Hilden, Germany) according to the manufacturers’ protocols. The
optimal transfection conditions were determined in separate titration exper-
iments. To control for unspeciﬁc effects, control cells were treated with
AllStars Negative Control siRNA (QIAGEN). These oligonucleotides have no
known similarities to human sequences and have no effect on gene expression
and metabolism of human in vitro–differentiated adipocytes (18). Cells were
incubated for 48 h and conditioned media were analyzed for release of
glycerol and adipokines and/or palmitate oxidation (described below). Cells
were subsequently lysed for RNA or protein extraction as described below.
Quantitative real-time RT-PCR. Cells were treated as described above and
total RNA was extracted using the NucleoSpin RNA II (Macherey-Nagel,
Du ¨ren, Germany). RNA concentration and purity were assessed spectropho-
tometrically with a NanoDrop ND-1000 (Thermo Scientiﬁc, Wilmington, DE)
and with an Agilent Bioanalyzer. Half a microgram of total RNA was
reverse-transcribed to cDNA using Omniscript reverse transcription kit (QIA-
GEN) and random hexamer primers (Invitrogen, Carlsbad, CA). For SYBR
Green assays, 5 ng of cDNA was mixed with 2	 iQ SYBR Green Supermix
(Eurogentec SA, Ougre ´e, Belgium) and primers (Invitrogen) in a ﬁnal volume
of 25 l. cDNA (10 ng) was mixed with 2	 TaqMan Universal PCR Master Mix
(Applied Biosystems, Foster City, CA) and TaqMan primers (Applied Biosys-
tems) in a ﬁnal volume of 20 l. Primer sequences and catalog numbers are
listed in supplementary Tables 1 and 2, available in an online appendix at
http://diabetes.diabetesjournals.org/cgi/content/full/db09-0997/DC1. Quantita-
tive RT-PCR was performed in an iCycler IQ (Bio-Rad Laboratories, Hercules,
CA). mRNA levels were determined by a comparative threshold cycle (Ct)
method. Ct values were normalized to the reference genes glyceraldehyde
3-phosphate dehydrogenase (GAPDH), LDL receptor–related protein 10
(LRP10), or 18S, according to the formula 2

Cttarget gene/2

Ctreference gene 
arbitrary units (AU). The PCR efﬁciency in all runs was close to 100%, and all
samples were run in duplicate.
For determination of twist1 mRNA in human SVF of WAT, RNA was
extracted using RNeasy kit from QIAGEN. RNA concentrations were mea-
sured by ﬂuorimetric assay (Ribogreen; Invitrogen) and reverse-transcribed
using the Superscript II kit (Invitrogen). Reverse transcription was also
performed without the superscript enzyme on RNA samples to ensure the
absence of contaminating genomic DNA. The ampliﬁcation reaction was
performed in duplicate on 15 ng of the cDNA samples in a ﬁnal volume of 20
l in 96-well reaction plates (Applied Biosystems) in a GeneAmp 7500
detection system (Applied Biosystems).
Palmitate oxidation. Cells were treated with siRNA for 48 h as described
above. The medium was subsequently changed to a glucose-free medium
supplemented with 2 mmol/l L-carnitine, 1% FA-free BSA,
14C-labeled palmi-
tate, and unlabeled palmitate for 3 h. FA oxidation was measured as described
(19). Liberated
14CO2 (free fraction) was collected on Carbosorb and
14C-
labeled -oxidation metabolites (acid-soluble fraction) were extracted using
butanol. Both fractions were measured by scintillation counting. The cells
were lysed for RNA and/or protein, and palmitate/FA oxidation (total counts
from both fractions) was normalized to protein amount in each experimental
group. All conditions were measured in duplicate or triplicate.
Lipolysis measurements. Condition medium aliquots were taken from in
vitro–differentiated adipocytes. Glycerol release into the medium (mol/l)
was used as a measurement of the lipolysis rate and was analyzed using a
bioluminescence method (20).
Western blotting. Cells were lysed in radioimmunoprecipitation assay buffer
and protein concentrations were measured as previously described (18).
Protein lysates were boiled in 1	 SDS loading buffer, separated by SDS-PAGE,
and blotted as described before (21). Antibodies were -twist1 (catalog
number T6451; Sigma, St. Louis, MO) and --actin (catalog number A2066;
Sigma). Antibody-antigen complexes were detected by chemiluminescence
using the Chemidoc XRS system (Bio-Rad Laboratories), and images were
analyzed using Quantity One Software (Bio-Rad Laboratories).
Adipokine measurements. Human IL-6, monocyte chemoattractant pro-
tein-1 (MCP-1), and adiponectin were measured in medium aliquots using a
Quantikine Immunoassay for human IL-6 (catalog number D6050), MCP-1
(catalog number DCP00), or adiponectin (catalog number DRP300), respec-
tively (R&D Systems, Minneapolis, MN), according to the manufacturer’s
instructions.
Chromatin immunoprecipitation. ChIP was performed using a kit (Acetyl-
Histone H4 Immunoprecipitation [ChIP] Assay Kit, catalog number 17-229;
Millipore, Temecula, CA) designed for detecting transcriptionally active
chromatin from mammalian cells. ChIP was performed according to the
manufacturer’s instructions. Sonication conditions were optimized in separate
experiments to produce 200- to 1,000-base pair (bp) DNA fragments. Immu-
noprecipitation was performed with -twist1 (catalog number T6451; Sigma)
or -acetyl-histone H4 antibodies overnight at 4°C. Anti-GLUT4 (catalog
number 4670-1704; AbD Serotec, Oxford, U.K.) or no antibody was used as
negative control.
The extracted DNA was used for PCR analysis. PCRs were conducted using
primers spanning regions in human MCP-1, TNF-, and IL-6 promoters. Primer
sequences and PCR product sizes are listed in supplementary Table 3. All
primers were designed to amplify promoter regions spanning E-boxes pre-
dicted by MatInspector software from Genomatix BiblioSphere. PCRs were
carried out at 25 l in the following conditions: 94°C for 3 min, followed by 32
cycles of 94°C for 30 s, 55/58/60°C for 30 s (depending on primer pair), 72°C
for 45 s, and a ﬁnal step at 72°C for 10 min. PCR products were separated on
2% agarose gels and visualized by ethidium bromide staining.
Reporter assays. The pIL6 promoter construct was a gift from Dr Chiara
Constanzo at the University of Verona, Italy, and has been described in detail
elsewhere (22). In brief, it was constructed from a part of the human IL-6
promoter, spanning from 541 to 68, relative to the transcriptional start
site (NM_000600), inserted into the pGL2-basic vector (Promega, Madison,
WI). This promoter fragment spans several E-boxes predicted by MatIn-
spector software and overlaps with the region ampliﬁed with the ChIP
primers IL-6 proximal (supplementary Table 3). For construction of the
twist1 expression vector, the coding sequence for human twist1 was
excised from Full-Length Mammalian Gene Collection, Clone 4125830
(reference sequence Hs.66744) (Invitrogen) and cloned into pcDNA3.1
(Invitrogen). Expression of twist1 was conﬁrmed by in vitro translation
using a TnT T7/SP6 Coupled Reticulocyte Lysate System (catalog number
L5020; Promega). Gene reporter assays were performed in undifferentiated
3T3-L1 cells transfected with Lipofectamine and Plus reagent (both from
Invitrogen) as described (23) using 0.2 g of pGL2-basic or pIL6 together
with either 0.2 g of pcDNA3.1 carrying the human twist1 sequence
(pTwist1) or the empty expression vector pcDNA3.1. A cytomegalovirus-
-galactosidase–containing vector (0.1 g) was included in all transfec-
tions to control for transfection efﬁciency. Luciferase activity, was
normalized for -galactosidase activity, and all experiments were run in
triplicate and repeated at least four times.
Statistical analysis. Values shown are mean  SEM. Results were analyzed
with suitable nonparametric statistical methods including Mann-Whitney,
Wilcoxon, and Friedman tests.
A.T. PETTERSSON AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, MARCH 2010 565RESULTS
Twist1 is expressed predominantly in the adipocytes
of human WAT. Twist1 and twist2 mRNA expression was
investigated by quantitative RT-PCR in paired samples
from human WAT, liver, pancreas, and skeletal muscle
(Fig. 1A, cohort 1). Twist1 was detected only in WAT,
whereas twist2 mRNA expression was readily detected in
all examined tissues (Fig. 1A) and at similar levels in
adipose tissue, liver, and pancreas. In paired samples of
human WAT and isolated adipocyte fractions, twist1 ap-
peared to be expressed predominantly in adipocytes be-
cause twist1 mRNA levels were higher in the adipocyte
fraction compared with WAT (Fig. 1B, cohort 2). This was
conﬁrmed in a more detailed cell fraction analysis of
adipose tissue demonstrating that twist1 expression was
signiﬁcantly higher in adipocytes compared with macro-
phages, endothelial cells, or cells expressing neither CD34,
CD31, nor CD14 (Fig. 1C, cohort 3). Moreover, the expres-
sion of twist1 increased during in vitro differentiation of
human preadipocytes, reaching a maximum level at differ-
entiation day 8 (Fig. 1D).
Twist1 RNAi reduces FA oxidation but does not
inﬂuence lipolysis in human cultured adipocytes. To
assess biological functions of twist1 in human adipocytes,
we performed in vitro gene silencing of twist1 in human in
vitro–differentiated adipocytes using siRNA. The RNAi
treatment was efﬁcient and reduced the mRNA expression
of twist1 up to 95% (Fig. 2A, left panel). Twist1 protein
levels were also reduced, albeit to a lesser extent (35%,
Fig. 2A, right panel). This effect was selective because the
expression of twist2 mRNA (Fig. 2A) and several reference
genes (GAPDH and LRP10, values not shown) was not
affected by twist1 siRNA. In contrast to murine data, in
vitro downregulation of twist1 signiﬁcantly reduced FA
oxidation by 40% (P 
 0.05, n  3), measured as release
of CO2 and -oxidation metabolites into conditioned me-
dia (Fig. 2B). This effect was speciﬁc and not secondary to
off-target or dedifferentiating effects because lipolysis was
unaltered by twist1 gene silencing in similar experiments
(Fig. 2C). We also measured glucose transport in cultured
adipocytes treated with siRNA but did not observe any
differences between control- and twist1 siRNA—treated
cells (graph not shown).
Selective downregulation of gene expression after
twist1 RNAi in human cultured adipocytes. Given the
selective effect of twist1 downregulation, we measured the
mRNA levels of several genes involved in FA oxidation
(acyl-CoA synthetase [ACC2], CPT-1, acyl-CoA dehydro-
genases [SCAD, MCAD, and VLCAD], hydroxyacyl-CoA
dehydrogenase [HADHA], and -ketothiolase [HADHB]).
We also determined the expression of genes involved in
the regulation of substrate usage (pyruvate dehydrogenase
kinases 1 and 4 [PDK1/4]), as well as genes important for
brown (UCP-1, PGC-1) and white (hormone-sensitive
lipase [HSL], perilipin [PLIN], cell death–inducing DNA
fragmentation factor-–like effector A [CIDEA], and per-
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FIG. 1. Twist1 mRNA levels in different cell types from adipose tissue and during adipocyte differentiation. A: Twist1 and twist2 mRNA levels were
measured in paired samples from human white adipose tissue (n  3), liver (n  2), pancreas (panc., n  3), and skeletal muscle (sk. muscle, n 
3) (cohort 1). B: Twist1 expression was measured in 14 samples from human mature adipocytes (adip.) and the corresponding adipose tissue
(cohort 2). C: Twist1 was also measured in samples from human mature adipocytes (n  6) and the corresponding CD34
/CD31
 capillary
endothelial cells (endo., n  10), CD14
/CD34
 resident macrophages (mac., n  9), and cells negative for CD34, CD31, and CD14 (neg., n  10)
(cohort 3). D: Twist1 mRNA levels were measured during in vitro differentiation of human preadipocytes, n  9. Cells were lysed at days 4, 8, and
12 of differentiation. RNA from earlier stages is not relevant to isolate because other types of cells from the stroma-vascular fraction (e.g.,
endothelial cells) may be present during the ﬁrst few days of cell culture. Nonadipocyte cells are, however, not supported in the adipogenic
differentiation medium and consequently die off at approximately day 2. All mRNA levels were normalized to the reference gene 18S and are
shown as arbitrary units (A.U.). Bars indicate mean  SEM. ND, not detected. ***P < 0.0001, **P < 0.01, and *P < 0.05.
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pocyte function. Only CPT-1 and PGC-1 were signiﬁ-
cantly reduced (25%) after siRNA treatment, but there
were no signiﬁcant effects on the expression of other
genes involved in FA oxidation (Fig. 2D). In accordance
with the unaltered lipolytic capacity in twist1 siRNA–
A
siTwist1 
protein
siRNA:
 
α-twist1 
α-β-actin
ctrl 
B
D
C Lipolysis 
20 
40
60
80
100
120
140
µ
M
 
g
l
y
c
e
r
o
l
(
%
o
f
 
c
o
n
t
r
o
l
)
 
ctrl siTwist1 siRNA: 
NS 
0
* 
mRNA 
ctrl  siTwist1   siRNA:  
NS 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
twist1 twist2
R
e
l
a
t
i
v
e
 
e
x
p
r
e
s
s
i
o
n
0
20
40
60
80
100
120
* 
ctrl siTwist1 siRNA: 
β-oxidation  
A
.
U
.
 
(
%
 
o
f
 
c
o
n
t
r
o
l
)
R
e
l
a
t
i
v
e
 
m
R
N
A
 
e
x
p
r
e
s
s
i
o
n
 
C
o
n
t
r
o
l
 
s
i
R
N
A
 
P
D
K
1
 
P
D
K
4
 
Substrate
regulation
β-oxidation
C
P
T
1
 
S
C
A
D
 
M
C
A
D
 
V
L
C
A
D
 
H
A
D
H
A
 
H
A
D
H
B
 
A
C
C
2
 
* 
BAT
U
C
P
1
 
P
G
C
1
α
* 
WAT
H
S
L
 
P
L
I
N
 
P
P
A
R
γ
C
I
D
E
A
  0
0.5
1
1.5
2
2.5
FIG. 2. In vitro silencing of twist1 in human cultured adipocytes. Human in vitro–differentiated adipocytes were treated with 50 nmol/l control
siRNA or siRNA directed against twist1. A: Twist1 and twist2 mRNA was measured; n  5( left panel). Twist1 protein levels were measured by
Western blot and normalized for -actin (right panel). The result shown is a representative experiment. The effect of siRNA at the protein level
was less pronounced than that at the mRNA level, a ﬁnding that we have observed previously for several other genes (18,31). B: FA oxidation was
measured in conditioned media from adipocytes treated with siRNA as above. C: Lipolysis was measured as release of glycerol into conditioned
media from adipocytes treated with siRNA as above. D: mRNA levels of a set of genes were measured after siRNA treatment (n  3–6). mRNA
levels were normalized to the reference gene GAPDH. Results shown are mean  SEM, and all mRNA levels are shown as relative expression (fold
change to control siRNA). *P < 0.05.
A.T. PETTERSSON AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, MARCH 2010 567treated cells, the expression of HSL, PLIN, CIDEA, and
PPAR was not changed, further suggesting that there
were no off-target effects of siRNA treatment.
Twist1 RNAi suggests a role in the regulation of
adipokine production. Because Twist1 appears to be
involved in inﬂammatory pathways and in order to
screen for additional functional roles of twist1, we
assessed the effect of twist1 RNAi on a set of genes
coding for adipokines. The expression of IL-6, TNF-,
and MCP-1 was markedly reduced in cells treated with
twist1 siRNA compared with control-treated cells (Fig.
3A). This effect was selective because the expression of
the fat-speciﬁc secreted factor adiponectin was not
affected (Fig. 3A). To determine whether mRNA changes
were reﬂected at the protein level, we measured the
release of adipokines in conditioned media from the
same experiments. Silencing of twist1 reduced the re-
lease of IL-6 by 20% (P 
 0.01, n  5) and MCP-1 by
40% (P 
 0.05, n  3) (Fig. 3B and C), whereas the
release of adiponectin was unaltered (P  0.59, n  3)
(Fig. 3D). The protein levels of TNF- in the medium
were below the detection limit of our assay.
Twist1 binds to human MCP-1, IL-6, and TNF- pro-
moters. Because twist1 is a transcription factor, it
can directly regulate the transcriptional expression of
MCP-1, IL-6, and TNF- by binding to E-boxes in the
promoter regions of these genes. Using MatInspector
software, we identiﬁed putative E-boxes in the promoter
regions of these genes and designed PCR primers, which
would generate PCR products overlapping them. We
then performed ChIP analysis on human in vitro–differ-
entiated adipocytes and were able to amplify E-box–
containing regions from MCP-1, TNF-, as well as IL-6
(Fig. 4A), suggesting that twist1 directly binds to these
promoter regions in vivo. The binding of twist1 was
speciﬁc because we could not detect any PCR products
using another set of primers designed to generate a PCR
fragment overlapping an E-box more upstream in the
TNF- promoter.
To verify the interaction between twist1 and cytokine
promoters, we performed transient transfections using a
luciferase reporter construct coupled to 609 bp of the
human IL-6 promoter (which overlaps the proximal region
ampliﬁed in the ChIP experiments) together with an
expression vector containing the cDNA of human twist1.
Assays were performed in undifferentiated 3T3-L1 cells.
Coexpression of twist1 signiﬁcantly reduced the activity of
the IL-6 promoter compared with control cells cotrans-
fected with an empty vector (Fig. 4B), suggesting that
twist1 indeed inﬂuences the transcriptional activity of this
promoter.
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Release of IL-6 (B), MCP-1 (C), and adiponectin (D) was measured in conditioned media; n  4 (IL-6) and n  3 (MCP-1/adiponectin). Results shown
are mean  SEM and mRNA levels are shown as relative expression (fold change to control siRNA). **P < 0.01, *P < 0.05.
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Although studies in mice suggest that twist1 is important
in the regulation of BAT energy metabolism and inﬂam-
matory pathways, the role of this factor in WAT function
has thus far been unknown. This is the ﬁrst study of twist1
in white fat cells.
Among four different human organs of importance for
metabolism, twist1 was expressed only in human WAT.
This selective expression pattern is similar to the expres-
sion pattern observed in adult mice (14). In contrast,
twist2 mRNA could readily be detected in liver, muscle,
pancreas, and WAT. In mice, twist2 mRNA is detected in
both fat tissue and liver, and ob/ob and db/db mice were
reported to display elevated levels of twist protein in fat
tissue (24). It is not clear whether these proteins represent
twist2 or a mix of both twist proteins. Nevertheless, this
suggests that twist2 has a different role than twist1. With
regard to intra-organ expression of twist1, our cellular
expression analysis, using two independent methods, dem-
onstrates that twist1 expression is considerably higher in
adipocytes than in other cell types of human WAT. First,
the expression levels in isolated adipocytes were higher
than in the corresponding adipose tissue from different
donors. Second, when analyzing the expression in differ-
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cantly higher than in macrophages, endothelial cells, or a
CD34-, CD31-, and CD14-negative cell population isolated
from the same adipose tissue. Twist1 expression also
increased during in vitro differentiation of preadipocytes,
further supporting a functional role in mature adipocytes.
Interestingly, twist1 expression decreases during myoblast
and osteoblast differentiation (6–9), supporting the notion
that twist1 has tissue-speciﬁc functions.
In humans, FA oxidation in WAT is normally of minor
signiﬁcance and accounts for only a small percentage of
the total FA oxidation in the body (25). However, in
certain speciﬁc conditions (e.g., cancer cachexia), lipid
oxidation in human white adipocytes may increase signif-
icantly (26). PGC-1 is a pivotal regulator in brown fat
cells, and overexpression in human white adipocytes
results in a more brown phenotype that is characterized by
increased FA oxidation and oxygen consumption (19). In
murine brown fat cells, twist1 knockdown leads to in-
creased expression of PGC-1 target genes and increased
mitochondrial biogenesis (14). Furthermore, high-fat feed-
ing of transgenic mice overexpressing twist1 under the
fat-speciﬁc adipocyte fatty acid–binding protein promoter
results in decreased expression of UCP-1 and FA oxida-
tion genes in BAT. FA oxidation was not directly measured
in brown fat cells but was shown to be reduced in C2C12
myotubes (14). These transgenic mice are more prone to
diet-induced obesity with increased lipid accumulation in
brown adipocytes. Interestingly, even though the adipo-
cyte fatty acid–binding protein promoter is active in WAT
as well, there was no effect on gene expression in this
tissue, supporting the notion that twist1 selectively and
negatively regulates BAT metabolism in mice (14). In
contrast to these results, our RNAi experiments in human
in vitro–differentiated adipocytes demonstrate that twist1
downregulation reduced FA oxidation as well as the
mRNA expression of PGC-1 and the rate-limiting enzyme
for FA oxidation, CPT-1. Moreover, the effect on lipid
metabolism seems restricted to this process because basal
lipolysis was unaltered. Therefore, under the present study
conditions, twist1 appears to be a positive regulator of FA
oxidation in human white adipocytes, possibly via effects
on CPT-1 and PGC-1. It should be stressed that although
twist1 was reported to be expressed at similar levels in
murine WAT compared with BAT (14), the functional role
of twist1 in murine WAT has thus far not been assessed. At
present, it is therefore not possible to establish whether
there are qualitative differences in the function of twist1 in
human versus murine fat cells or if the contrasting data
between the present and previous study (14) merely reﬂect
different roles of twist1 in brown and white adipocytes.
Nevertheless, because FA oxidation in white adipocytes is
normally of minor physiological importance, it is difﬁcult
to speculate on the impact of these ﬁndings at the in vivo
level. Although recent studies demonstrate the existence
of brown adipocytes in adult humans (27–29), it is not
possible for ethical reasons to obtain sufﬁcient amounts
of human brown fat cells for mechanistic studies in
vitro. Therefore, we did not continue with direct mech-
anistic studies of FA oxidation but searched for addi-
tional and possibly more important roles for twist1 in
white adipocytes.
Results from twist knockout mice suggest that twist1
and twist2 regulate cytokine signaling by repressing nu-
clear factor-B–dependent cytokine activation (5). Our
adipocyte gene silencing data also imply a role for twist1
in the regulation of inﬂammatory cytokines, although
somewhat different from that in mice, because mRNA
expression of TNF-, IL-6, and MCP-1 was downregulated
and the secretion of the latter two was attenuated in
twist1-silenced cells. This effect was speciﬁc, because
adiponectin mRNA expression and secretion were unal-
tered. The discrepancy between the ﬁndings in knockout
mice and our adipocyte gene silencing experiments may
be due to species-speciﬁc differences, although one cannot
exclude the possibility that a partial or complete lack of
twist in all cell types (as in the knockout models) may
result in different effects compared with cell-speciﬁc gene
knockdowns in vitro.
Our ChIP analysis demonstrated that twist1 directly
interacts with speciﬁc promoter regions of all three inﬂam-
matory factors, thereby suggesting a direct regulatory role
of twist1. Furthermore, IL-6 promoter activity was signif-
icantly reduced when twist1 was coexpressed in undiffer-
entiated murine 3T3-L1 cells. This further strengthens the
notion that twist1 affects the activity of the human IL-6
promoter via a direct interaction. Admittedly, the effects in
the gene reporter assays may at ﬁrst appear to be in
contrast with the siRNA data where transient twist1 silenc-
ing reduced IL-6 mRNA expression and secretion. How-
ever, it is well known that promoter activity in plasmid
DNA can differ signiﬁcantly from that in an intact chroma-
tin environment (30). In addition, it should be stressed that
the reporter assays were performed in undifferentiated
murine ﬁbroblasts using human twist1 and a short part of
the human IL-6 promoter sequence. Therefore, the sup-
pressive effect of twist1 on the IL-6 promoter could be
secondary to the cell type used in these experiments
and/or absence of appropriate endogenous regulatory co-
factors. The most relevant interpretation of the reporter
data is that twist1 binds and regulates the IL-6 promoter.
Taken together, our results from siRNA, ChIP, and re-
porter assays reﬂect the same mechanism: a regulatory
role of twist1 in inﬂammatory pathways.
In summary, the transcription factor twist1 is expressed
predominantly in human white adipocytes. In vitro gene
silencing results in attenuated expression and secretion of
several inﬂammatory adipokines but also in reduced FA
oxidation, which is in contrast to ﬁndings in mice. We
therefore propose a novel function for twist1 as a possible
regulator of inﬂammatory adipokines. Given the rather
low quantitative role of FA oxidation in human WAT, the
effects of twist1 on this process may be less important.
ACKNOWLEDGMENTS
This work was supported by several grants from the
Swedish Heart and Lung Foundation, Swedish Diabetes
Association, Storstockholms Diabetesfo ¨rening, Torsten
och Ragnar So ¨derberg Foundation, Novo Nordisk Foun-
dation, the European Union (HEPADIP, LSHM-CT-2005-
018734), ADAPT (HEALTH-F2-2008-201100), COST action
(BM0602), NordForsk (SYSDIET-070014), the Swedish Med-
ical Association, and the Swedish Diabetes Foundation.
No potential conﬂicts of interest relevant to this article
were reported.
We thank Elisabeth Dungner, Eva Sjölin, Kerstin
Wåhle ´n, Gaby Åstro ¨m, Britt-Marie Leijonhufvud, and
Katarina Hertel for excellent technical assistance. We
thank Chiara Costanzo, University of Verona, Italy, for
the pIL6 construct.
Twist1 AND WHITE ADIPOCYTES
570 DIABETES, VOL. 59, MARCH 2010 diabetes.diabetesjournals.orgREFERENCES
1. Wang SM, Coljee VW, Pignolo RJ, Rotenberg MO, Cristofalo VJ, Sierra F.
Cloning of the human twist gene: its expression is retained in adult
mesodermally-derived tissues. Gene 1997;187:83–92
2. Castanon I, Baylies MK. A Twist in fate: evolutionary comparison of Twist
structure and function. Gene 2002;287:11–22
3. El Ghouzzi V, Legeai-Mallet L, Benoist-Lasselin C, Lajeunie E, Renier D,
Munnich A, Bonaventure J. Mutations in the basic domain and the
loop-helix II junction of TWIST abolish DNA binding in Saethre-Chotzen
syndrome. FEBS Lett 2001;492:112–118
4. Chen ZF, Behringer RR. Twist is required in head mesenchyme for cranial
neural tube morphogenesis. Genes Dev 1995;9:686–699
5. Sosic ´ D, Richardson JA, Yu K, Ornitz DM, Olson EN. Twist regulates
cytokine gene expression through a negative feedback loop that represses
NF-kappaB activity. Cell 2003;112:169–180
6. Bialek P, Kern B, Yang X, Schrock M, Sosic D, Hong N, Wu H, Yu K, Ornitz
DM, Olson EN, Justice MJ, Karsenty G. A twist code determines the onset
of osteoblast differentiation. Dev Cell 2004;6:423–435
7. Isenmann S, Arthur A, Zannettino AC, Turner JL, Shi S, Glackin CA,
Gronthos S. TWIST family of basic helix-loop-helix transcription factors
mediate human mesenchymal stem cell growth and commitment. Stem
Cells 2009;27:2457–2468
8. Spicer DB, Rhee J, Cheung WL, Lassar AB. Inhibition of myogenic bHLH
and MEF2 transcription factors by the bHLH protein Twist. Science
1996;272:1476–1480
9. Gong XQ, Li L. Dermo-1, a multifunctional basic helix-loop-helix protein,
represses MyoD transactivation via the HLH domain, MEF2 interaction,
and chromatin deacetylation. J Biol Chem 2002;277:12310–12317
10. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C,
Savagner P, Gitelman I, Richardson A, Weinberg RA. Twist, a master
regulator of morphogenesis, plays an essential role in tumor metastasis.
Cell 2004;117:927–939
11. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin
resistance and type 2 diabetes. Nature 2006;444:840–846
12. Niesner U, Albrecht I, Janke M, Doebis C, Loddenkemper C, Lexberg MH,
Eulenburg K, Kreher S, Koeck J, Baumgrass R, Bonhagen K, Kamradt T,
Enghard P, Humrich JY, Rutz S, Schulze-Topphoff U, Aktas O, Bartfeld S,
Radbruch H, Hegazy AN, Lo ¨hning M, Baumgart DC, Duchmann R, Rudwa-
leit M, Ha ¨upl T, Gitelman I, Krenn V, Gruen J, Sieper J, Zeitz M,
Wiedenmann B, Zipp F, Hamann A, Janitz M, Scheffold A, Burmester GR,
Chang HD, Radbruch A. Autoregulation of Th1-mediated inﬂammation by
twist1. J Exp Med 2008;205:1889–1901
13. Sharif MN, Sosic D, Rothlin CV, Kelly E, Lemke G, Olson EN, Ivashkiv LB.
Twist mediates suppression of inﬂammation by type I IFNs and Axl. J Exp
Med 2006;203:1891–1901
14. Pan D, Fujimoto M, Lopes A, Wang YX. Twist-1 is a PPARdelta-inducible,
negative-feedback regulator of PGC-1alpha in brown fat metabolism. Cell
2009;137:73–86
15. Arner P, Stenson BM, Dungner E, Na ¨slund E, Hoffstedt J, Ryden M,
Dahlman I. Expression of six transmembrane protein of prostate 2 in
human adipose tissue associates with adiposity and insulin resistance.
J Clin Endocrinol Metab 2008;93:2249–2254
16. Bourlier V, Zakaroff-Girard A, Miranville A, De Barros S, Maumus M,
Sengenes C, Galitzky J, Lafontan M, Karpe F, Frayn KN, Bouloumie ´A .
Remodeling phenotype of human subcutaneous adipose tissue macro-
phages. Circulation 2008;117:806–815
17. van Harmelen V, Skurk T, Hauner H. Primary culture and differentiation of
human adipocyte precursor cells. Methods Mol Med 2005;107:125–135
18. Stenson BM, Ryde ´n M, Steffensen KR, Wåhle ´n K, Pettersson AT, Jocken
JW, Arner P, Laurencikiene J. Activation of liver X receptor (LXR)
regulates substrate oxidation in white adipocytes. Endocrinology 2009;150:
4104–4113
19. Tiraby C, Tavernier G, Lefort C, Larrouy D, Bouillaud F, Ricquier D, Langin
D. Acquirement of brown fat cell features by human white adipocytes.
J Biol Chem 2003;278:33370–33376
20. Hellme ´r J, Arner P, Lundin A. Automatic luminometric kinetic assay of
glycerol for lipolysis studies. Anal Biochem 1989;177:132–137
21. Ryden M, Dicker A, van Harmelen V, Hauner H, Brunnberg M, Perbeck L,
Lonnqvist F, Arner P. Mapping of early signaling events in tumor necrosis
factor-alpha-mediated lipolysis in human fat cells. J Biol Chem 2002;277:
1085–1091
22. Faggioli L, Costanzo C, Donadelli M, Palmieri M. Activation of the
Interleukin-6 promoter by a dominant negative mutant of c-Jun. Biochim
Biophys Acta 2004;1692:17–24
23. Pettersson AT, Laurencikiene J, Nordstro ¨m EA, Stenson BM, van
Harmelen V, Murphy C, Dahlman I, Ryde ´n M. Characterization of the
human CIDEA promoter in fat cells. Int J Obes (Lond) 2008;32:1380–1387
24. Lee YS, Lee HH, Park J, Yoo EJ, Glackin CA, Choi YI, Jeon SH, Seong RH,
Park SD, Kim JB. Twist2, a novel ADD1/SREBP1c interacting protein,
represses the transcriptional activity of ADD1/SREBP1c. Nucleic Acid Res
2003;31:7165–7174
25. Frayn KN, Langin D, Karpe F. Fatty acid-induced mitochondrial uncou-
pling in adipocytes is not a promising target for treatment of insulin
resistance unless adipocyte oxidative capacity is increased. Diabetologia
2008;51:394–397
26. Laurencikiene J, Stenson BM, Arvidsson Nordstro ¨m E, Agustsson T,
Langin D, Isaksson B, Permert J, Ryde ´n M, Arner P. Evidence for an
important role of CIDEA in human cancer cachexia. Cancer Res 2008;68:
9247–9254
27. Cypess AM, Lehman S, Williams G, Tal I, Rodman D, Goldﬁne AB, Kuo FC,
Palmer EL, Tseng YH, Doria A, Kolodny GM, Kahn CR. Identiﬁcation and
importance of brown adipose tissue in adult humans. N Engl J Med
2009;360:1509–1517
28. van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM, Drossaerts
JM, Kemerink GJ, Bouvy ND, Schrauwen P, Teule GJ. Cold-activated
brown adipose tissue in healthy men. N Engl J Med 2009;360:1500–1508
29. Virtanen KA, Lidell ME, Orava J, Heglind M, Westergren R, Niemi T,
Taittonen M, Laine J, Savisto NJ, Enerba ¨ck S, Nuutila P. Functional brown
adipose tissue in healthy adults. N Engl J Med 2009;360:1518–1525
30. Smith CL, Hager GL. Transcriptional regulation of mammalian genes in
vivo: a tale of two templates. J Biol Chem 1997;272:27493–27496
31. Ryde ´n M, Jocken J, van Harmelen V, Dicker A, Hoffstedt J, Wire ´n M,
Blomqvist L, Mairal A, Langin D, Blaak E, Arner P. Comparative studies of
the role of hormone-sensitive lipase and adipose triglyceride lipase in
human fat cell lipolysis. Am J Physiol Endocrinol Metab 2007;292:E1847–
E1855
A.T. PETTERSSON AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, MARCH 2010 571